" class="no-js "lang="en-US"> Melinda Pryor - Medtech Alert
Sunday, October 19, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Melinda Pryor

Melinda Pryor

About Melinda Pryor

Co-founder with a wealth of experience in the design and implementation of large multi-centre international clinical trials. Melinda has more than 25 years’ experience in molecular virology and immunology and leads our high performing clinical team. Melinda is focussed on delivering regulatory compliant data and providing expert clinical support to our clients.

Related Story

Industry News

 BioAgilytix to Purchase Australia-Based 360biolabs® | Pharmtech Focus

BioAgilytix to Purchase Australia-Based 360biolabs®

August 16 2021

BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research laboratory focused on supporting its pharmaceutical […]